Combination Approaches and Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer

Slideset - The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research